Nikolay Dorokhov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nikolay Dorokhov has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- S. E. Mukhanova
Sechenov First Moscow State Medical University (Sechenov University)
2 shared publications - Aida I. Tarzimanova
Department of Faculty Therapy No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
1 shared publication - Aleksander A. Ivannikov
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Alexander Cherepanov
Department of Faculty Therapy No. 2, Sechenov First Moscow State Medical University (Sechenov University), 119048 Moscow, Russia
1 shared publication - Anna E. Pokrovskaya
I.M. Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication - Array E. Bragina
Sechenov First Moscow State Medical University (Sechenov University)
1 shared publication
Latest Publications
- Open Access
- 28 October 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (4) , 375-382
NR2-antibodies and cognitive impairment in patients with controlled hypertension
Aim . To investigate the relationship between cognitive impairment (CI) and serum NR2 antibody (NR2-AB) levels in patients with controlled hypertension (HTN) of stage I-II. Material and methods. A single-centre study included 105 patients (75 with essential HTN and 30 controls) aged 40–70 years. Serum NR2-AB levels were measured by enzyme-linked immunosorbent assay (ELISA), with a threshold of 1.8 ng/mL. Cognitive status was assessed using the Montreal Cognitive Assessment (MoCA): normal ≥26 points, CI ≤25 points. All patients with HTN received combination antihypertensive therapy and had achieved target blood pressure levels at inclusion. Results . NR2-AB levels were significantly higher in HTN patients (2.93 [1.46; 4.13] ng/mL) than in controls (1.35 [1.02; 2.09] ng/mL; p=0.001). CI was detected 8 times more frequently in HTN patients compared with controls (52% vs 6.7%). A negative correlation was observed between NR2-AB levels and MoCA scores (r= 0.2; p=0.048). Furthermore, a significant association between the marker and the presence of cognitive impairment was found in the univariate regression analysis (odds ratio=1.21; 95% confidence interval: 1.027-1.42; p=0.022), suggesting that this neuronal injury marker is linked to cognitive decline. ROC analysis revealed that an NR2-AB cutoff of 1.73 ng/mL had discriminative capacity for CI (sensitivity 71%, specificity 50%). In the multivariable logistic regression analysis, age, body mass index, and the presence of HTN were significantly associated with CI; the association with NR2-AB levels was not statistically significant (p=0.143). Conclusion . In patients with controlled stage I-II HTN, serum NR2AB levels are significantly elevated even after achieving target blood pressure. Age, body mass index, and HTN were significantly associated with CI.
- 28 October 2026
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 22 (4) , 375-382
Open AccessNR2-antibodies and cognitive impairment in patients with controlled hypertension
Aim . To investigate the relationship between cognitive impairment (CI) and serum NR2 antibody (NR2-AB) levels in patients with controlled hypertension (HTN) of stage I-II. Material and methods. A single-centre study included 105 patients (75 with essential HTN and 30 controls) aged 40–70 years. Serum NR2-AB levels were measured by enzyme-linked immunosorbent assay (ELISA), with a threshold of 1.8 ng/mL. Cognitive status was assessed using the Montreal Cognitive Assessment (MoCA): normal ≥26 points, CI ≤25 points. All patients with HTN received combination antihypertensive therapy and had achieved target blood pressure levels at inclusion. Results . NR2-AB levels were significantly higher in HTN patients (2.93 [1.46; 4.13] ng/mL) than in controls (1.35 [1.02; 2.09] ng/mL; p=0.001). CI was detected 8 times more frequently in HTN patients compared with controls (52% vs 6.7%). A negative correlation was observed between NR2-AB levels and MoCA scores (r= 0.2; p=0.048). Furthermore, a significant association between the marker and the presence of cognitive impairment was found in the univariate regression analysis (odds ratio=1.21; 95% confidence interval: 1.027-1.42; p=0.022), suggesting that this neuronal injury marker is linked to cognitive decline. ROC analysis revealed that an NR2-AB cutoff of 1.73 ng/mL had discriminative capacity for CI (sensitivity 71%, specificity 50%). In the multivariable logistic regression analysis, age, body mass index, and the presence of HTN were significantly associated with CI; the association with NR2-AB levels was not statistically significant (p=0.143). Conclusion . In patients with controlled stage I-II HTN, serum NR2AB levels are significantly elevated even after achieving target blood pressure. Age, body mass index, and HTN were significantly associated with CI.
- Open Access
Arterial Stiffness and Anti-NR2/GluN2 Autoantibodies to N-Methyl-D-Aspartate Receptors as Markers of Vascular Aging and Cognitive Impairment in Arterial Hypertension
Background: Arterial hypertension (HTN) is associated with accelerated vascular aging, cerebral microvascular injury, and cognitive decline. Anti-NR2/GluN2 (NR2) antibodies may be related to N-methyl-D-aspartate receptor (NMDAR)-mediated neuronal-ischemic injury, although their clinical significance in HTN requires further clarification. Objective: The aim of this study was to evaluate cross-sectional associations between arterial stiffness assessed by the cardio-ankle vascular index (CAVI), serum NR2 antibody levels, and cognitive performance assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in patients with essential HTN and controls. Methods: This single-center study included 175 adults aged 40–70 years: 128 patients with essential HTN and 47 controls. The median age was 58 [54; 66] years in the HTN group and 55 [47; 62] years in controls (p = 0.06). Men accounted for 52 patients (40.6%) in the HTN group and 14 participants (30.0%) in the control group (p = 0.22). Arterial stiffness was assessed using CAVI. Serum NR2 antibody levels were measured by enzyme-linked immunosorbent assay. Cognitive status was evaluated using MoCA and MMSE. Between-group comparisons, correlation analysis, and exploratory classification modeling were performed. Results: Patients with HTN had higher CAVI values than controls (8.3 [7.3; 9.4] vs. 7.3 [6.9; 7.9]; p = 0.001). Cognitive impairment was more frequent in hypertensive patients by both MoCA (52.3% vs. 27.7%; p = 0.003) and MMSE (48.7% vs. 28.3%; p = 0.01). NR2 antibody levels were higher in HTN (1.6 [1.15; 2.62] vs. 1.33 [1.02; 1.84] ng/mL; p = 0.03). CAVI inversely correlated with MoCA and MMSE scores. Conclusions: CAVI was higher in patients with HTN and showed modest inverse associations with cognitive scores. NR2 antibody levels were also higher in HTN; however, their relationship with cognitive impairment should be interpreted as exploratory and hypothesis-generating. Further longitudinal studies with neuroimaging are required to determine the clinical and prognostic significance of these findings.
Open AccessArterial Stiffness and Anti-NR2/GluN2 Autoantibodies to N-Methyl-D-Aspartate Receptors as Markers of Vascular Aging and Cognitive Impairment in Arterial Hypertension
Background: Arterial hypertension (HTN) is associated with accelerated vascular aging, cerebral microvascular injury, and cognitive decline. Anti-NR2/GluN2 (NR2) antibodies may be related to N-methyl-D-aspartate receptor (NMDAR)-mediated neuronal-ischemic injury, although their clinical significance in HTN requires further clarification. Objective: The aim of this study was to evaluate cross-sectional associations between arterial stiffness assessed by the cardio-ankle vascular index (CAVI), serum NR2 antibody levels, and cognitive performance assessed by the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) in patients with essential HTN and controls. Methods: This single-center study included 175 adults aged 40–70 years: 128 patients with essential HTN and 47 controls. The median age was 58 [54; 66] years in the HTN group and 55 [47; 62] years in controls (p = 0.06). Men accounted for 52 patients (40.6%) in the HTN group and 14 participants (30.0%) in the control group (p = 0.22). Arterial stiffness was assessed using CAVI. Serum NR2 antibody levels were measured by enzyme-linked immunosorbent assay. Cognitive status was evaluated using MoCA and MMSE. Between-group comparisons, correlation analysis, and exploratory classification modeling were performed. Results: Patients with HTN had higher CAVI values than controls (8.3 [7.3; 9.4] vs. 7.3 [6.9; 7.9]; p = 0.001). Cognitive impairment was more frequent in hypertensive patients by both MoCA (52.3% vs. 27.7%; p = 0.003) and MMSE (48.7% vs. 28.3%; p = 0.01). NR2 antibody levels were higher in HTN (1.6 [1.15; 2.62] vs. 1.33 [1.02; 1.84] ng/mL; p = 0.03). CAVI inversely correlated with MoCA and MMSE scores. Conclusions: CAVI was higher in patients with HTN and showed modest inverse associations with cognitive scores. NR2 antibody levels were also higher in HTN; however, their relationship with cognitive impairment should be interpreted as exploratory and hypothesis-generating. Further longitudinal studies with neuroimaging are required to determine the clinical and prognostic significance of these findings.